Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement
Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement
New era of early cancer detection blood tests on the horizon
Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19
New data presented at ESMO for multi-cancer early detection
Working to improve global cancer care access in low middle-income countries
Low-dose nivolumab leads to improved overall survival for head and neck cancer patients
Cancer patient symptom and physical function reporting by caregivers used as predictors of adverse clinical outcomes
War in Ukraine: Global cancer aid to support refugees
RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies
ASCO and WHO to collaborate on quality indicators for cancer facilities
Spotlight on global cancer control at ASCO 2022
ASCO 2022: Head and neck cancer highlights